Suspension of trading
Valuation Merrimack Pharmaceuticals
Stocks
MACK
US5903282094
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.13 USD | -0.13% |
|
-.--% | - |
| 24-05-20 | Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P Global BMI Index | CI |
| 24-05-20 | Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P TMI Index | CI |
Company Valuation: Merrimack Pharmaceuticals
Data adjusted to current consolidation scope
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 51.5 | 42.09 | 92.19 | 52.43 | 153.7 | 192 |
| Change | - | -18.27% | 119.01% | -43.12% | 193.09% | 24.96% |
| Enterprise Value (EV) 1 | -4.902 | 25.51 | 78.15 | 38.23 | 134.2 | 173.2 |
| Change | - | 620.48% | 206.32% | -51.08% | 251.13% | 29% |
| P/E | -1.27x | -2.43x | -30.4x | -21.4x | -100x | -162x |
| PBR | 0.88x | 2.43x | 5.76x | 3.7x | 8.46x | 10.3x |
| PEG | - | 0x | 0.4x | 1.1x | 2.7x | 5.9x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | 0.08x | -1.26x | -28.1x | - | - | - |
| EV / EBIT | 0.08x | -1.14x | -15.6x | -14.6x | -61.7x | -79.6x |
| EV / FCF | 0.12x | -1.57x | -46.9x | 52.8x | -185x | -153x |
| FCF Yield | 856% | -63.5% | -2.13% | 1.89% | -0.54% | -0.65% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -3.036 | -1.298 | -0.2263 | -0.1831 | -0.1142 | -0.0826 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -60.2 | -20.24 | -2.784 | - | - | - |
| EBIT 1 | -64.28 | -22.47 | -5.012 | -2.616 | -2.174 | -2.176 |
| Net income 1 | -40.51 | -17.33 | -3.028 | -2.455 | -1.544 | -1.181 |
| Net Debt 1 | -56.4 | -16.58 | -14.04 | -14.2 | -19.44 | -18.88 |
| Reference price 2 | 3.86 | 3.15 | 6.89 | 3.91 | 11.46 | 13.41 |
| Nbr of stocks (in thousands) | 13,343 | 13,363 | 13,380 | 13,410 | 13,410 | 14,321 |
| Announcement Date | 3/6/19 | 3/12/20 | 3/10/21 | 3/9/22 | 3/9/23 | 3/7/24 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 224M | |
| 34.06x | 5.97x | 18.46x | 0.97% | 48.5B | |
| -22.99x | 334.06x | -20.92x | -.--% | 38.97B | |
| 48.09x | 4.84x | 31.06x | -.--% | 35.43B | |
| 24.54x | 2.74x | 11.83x | -.--% | 33.65B | |
| 26.5x | 7.78x | 19.53x | 0.43% | 26.58B | |
| 31.4x | 5.06x | 23.02x | -.--% | 15.18B | |
| 23.86x | 2.05x | 9.01x | 1.1% | 13.89B | |
| 23.55x | 1.88x | 11.39x | -.--% | 12.76B | |
| Average | 23.62x | 45.55x | 12.92x | 0.31% | 25.02B | |
| Weighted average by Cap. | 22.66x | 61.82x | 12.08x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MACK Stock
- Valuation Merrimack Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
